1887

Microbial Genomics logo

Volume 7, Issue 12

Chemical biology-whole genome engineering datasets predict new antibacterial combinations Open Access

Abstract

Trimethoprim and sulfamethoxazole are used commonly together as cotrimoxazole for the treatment of urinary tract and other infections. The evolution of resistance to these and other antibacterials threatens therapeutic options for clinicians. We generated and analysed a chemical-biology-whole-genome data set to predict new targets for antibacterial combinations with trimethoprim and sulfamethoxazole. For this we used a large transposon mutant library in BW25113 where an outward-transcribing inducible promoter was engineered into one end of the transposon. This approach allows regulated expression of adjacent genes in addition to gene inactivation at transposon insertion sites, a methodology that has been called TraDIS-. These chemical genomic data sets identified mechanisms for both reduced and increased susceptibility to trimethoprim and sulfamethoxazole. The data identified that over-expression of FolA reduced trimethoprim susceptibility, a known mechanism for reduced susceptibility. In addition, transposon insertions into the genes , , , , , and increased susceptibility to trimethoprim and likewise for , , , and with sulfamethoxazole, while insertions in , , , , , and increased susceptibility to both these antibiotics. Two of these genes’ products, Tdk and IspD, are inhibited by AZT and fosmidomycin respectively, antibiotics that are known to synergise with trimethoprim. Thus, the data identified two known targets and several new target candidates for the development of co-drugs that synergise with trimethoprim, sulfamethoxazole or cotrimoxazole. We demonstrate that the TraDIS- technology can be used to generate information-rich chemical-genomic data sets that can be used for antibacterial development.

  • Received:
  • Accepted:
  • Published Online:
Keyword(s): antibiotics , chemical , combinations , genomics , TIS and TraDIS
Funding
This study was supported by the:
  • Biotechnology and Biological Sciences Research Council (Award BBS/E/F/000PR10349)
    • Principle Award Recipient: IanCharles
  • Biotechnology and Biological Sciences Research Council (Award BB/R012504/1)
    • Principle Award Recipient: IanCharles
© 2021 The Authors
  • This is an open-access article distributed under the terms of the Creative Commons Attribution License.
Loading

Article metrics loading...

/content/journal/mgen/10.1099/mgen.0.000718
2021-12-07
2024-04-20
Loading full text...

Full text loading...

/deliver/fulltext/mgen/7/12/mgen000718.html?itemId=/content/journal/mgen/10.1099/mgen.0.000718&mimeType=html&fmt=ahah

References

  1. Dolk FCK, Pouwels KB, Smith DRM, Robotham JV, Smieszek T et al. Antibiotics in primary care in England: which antibiotics are prescribed and for which conditions?. J Antimicrob Chemother 2018; 73:ii2–ii10 [View Article]
     [Google Scholar]
  2. Wróbel A, Arciszewska K, Maliszewski D, Drozdowska D et al. Trimethoprim and other nonclassical antifolates an excellent template for searching modifications of dihydrofolate reductase enzyme inhibitors. J Antibiot (Tokyo) 2020; 73:5–27 [View Article] [PubMed]
     [Google Scholar]
  3. Palmer AC, Kishony R. Opposing effects of target overexpression reveal drug mechanisms. Nat Commun 2014; 5:4296 [View Article] [PubMed]
     [Google Scholar]
  4. Bryce A. Global prevalence of antibiotic resistance in paediatric urinary tract infections caused by Escherichia coli and association with routine use of antibiotics in primary care: systematic review and meta-analysis. BMJ 2016; 352:
     [Google Scholar]
  5. Gangcuangco LM, Alejandria M, Henson KE, Alfaraz L, Ata RM et al. Prevalence and risk factors for trimethoprim-sulfamethoxazole-resistant Escherichia coli among women with acute uncomplicated urinary tract infection in a developing country. Int J Infect Dis 2015; 34:55–60 [View Article]
     [Google Scholar]
  6. Gupta K. International clinical practice guidelines for the treatment of acute uncomplicated cystitis and pyelonephritis in women: A 2010 update by the Infectious Diseases Society of America and the European Society for Microbiology and Infectious Diseases. Clin Infect Dis 2011; 52:e103–e120
     [Google Scholar]
  7. Lee DS, Lee S-J, Choe H-S. Community-acquired urinary tract infection by Escherichia coli in the era of antibiotic resistance. Biomed Res Int 2018; 2018:7656752
     [Google Scholar]
  8. Lee JC, Oh JY, Cho JW, Park JC, Kim JM et al. The prevalence of trimethoprim-resistance-conferring dihydrofolate reductase genes in urinary isolates of Escherichia coli in Korea. J Antimicrob Chemother 2001; 47:599–604 10.1093/jac/47.5.599
    [Google Scholar]
  9. Sanchez GV, Master RN, Karlowsky JA, Bordon JM. In vitro antimicrobial resistance of urinary Escherichia coli isolates among U.S. outpatients from 2000 to 2010. Antimicrob Agents Chemother 2012; 56:2181–2183
     [Google Scholar]
  10. Šeputienė V, Povilonis J, Ružauskas M, Pavilonis A, Sužiedėlienė E et al. Prevalence of trimethoprim resistance genes in Escherichia coli isolates of human and animal origin in Lithuania. J Med Microbiol 2010; 59:315–322 [View Article]
     [Google Scholar]
  11. Tagg KA, Francois Watkins L, Moore MD, Bennett C, Joung YJ et al. Novel trimethoprim resistance gene dfrA34 identified in Salmonella Heidelberg in the USA. J Antimicrob Chemother 2019; 74:38–41 [View Article]
     [Google Scholar]
  12. Vazouras K, Velali K, Tassiou I, Anastasiou-Katsiardani A, Athanasopoulou K et al. Antibiotic treatment and antimicrobial resistance in children with urinary tract infections. J Glob Antimicrob Resist 2020; 20:4–10 [View Article]
     [Google Scholar]
  13. Garrison J, Hooton TM. Fluoroquinolones in the treatment of acute uncomplicated urinary tract infections in adult women. Expert Opin Pharmacother 2001; 2:1227–1237
     [Google Scholar]
  14. Flensburg J, Skold O. Massive overproduction of dihydrofolate reductase in bacteria as a response to the use of trimethoprim. Eur J Biochem 1987; 162:473–476 [View Article]
     [Google Scholar]
  15. Gingras H, Patron K, Bhattacharya A, Leprohon P, Ouellette M et al. Gain- and loss-of-function screens coupled to next-generation sequencing for antibiotic mode of action and resistance studies in Streptococcus pneumoniae. Antimicrob Agents Chemother 2019; 63:e02381-18 [View Article] [PubMed]
     [Google Scholar]
  16. Volpato JP, Pelletier JN. Mutational ‘hot-spots’ in mammalian, bacterial and protozoal dihydrofolate reductases associated with antifolate resistance: Sequence and structural comparison. Drug Resistance Updates 2009; 12:28–41 [View Article]
     [Google Scholar]
  17. Watson M, Liu J-W, Ollis D. Directed evolution of trimethoprim resistance in Escherichia coli . FEBS J 2007; 274:2661–2671 [View Article]
     [Google Scholar]
  18. White PA. Characterisation of two new gene cassettes, aadA5 and dfrA17. FEMS Microbiol Lett 2000; 182:265–269
     [Google Scholar]
  19. Yasir M, Turner AK, Bastkowski S, Baker D, Page AJ et al. TraDIS-Xpress: a high-resolution whole-genome assay identifies novel mechanisms of triclosan action and resistance. Genome Res 2020; 30:239–249 [View Article] [PubMed]
     [Google Scholar]
  20. Baba T, Ara T, Hasegawa M, Takai Y, Okumura Y et al. Construction of Escherichia coli K‐12 in‐frame, single‐gene knockout mutants: the Keio collection. Mol Syst Biol 2006; 2: [View Article]
     [Google Scholar]
  21. Page AJ, Bastkowski S, Yasir M, Turner AK, Le Viet T et al. AlbaTraDIS: Comparative analysis of large datasets from parallel transposon mutagenesis experiments. PLoS Comput Biol 2020; 16:e1007980 [View Article]
     [Google Scholar]
  22. Barquist L, Mayho M, Cummins C, Cain AK, Boinett CJ et al. The TraDIS toolkit: sequencing and analysis for dense transposon mutant libraries. Bioinformatics 2016; 32:1109–1111 [View Article] [PubMed]
     [Google Scholar]
  23. Carver T, Harris SR, Berriman M, Parkhill J, McQuillan JA et al. Artemis: an integrated platform for visualization and analysis of high-throughput sequence-based experimental data. Bioinformatics 2012; 28:464–469 [View Article] [PubMed]
     [Google Scholar]
  24. Bastian M, Heymanns S, Jacomy M. Gephi: an open source software for exploring and manipulating networks, in International AAAI Conference on Weblogs and Social Media 2009
     [Google Scholar]
  25. Shannon P et al. Cytoscape: a software environment for integrated models of biomolecular interaction networks. Genome Research 2003; 13:2498–2504 [View Article]
     [Google Scholar]
  26. Turner AK et al. A whole-genome screen identifies Salmonella enterica serovar Typhi genes involved in fluoroquinolone susceptibility. J Antimicrob Chemother 2020; 75:2516–2525
     [Google Scholar]
  27. Turner AK. A genome-wide analysis of Escherichia coli responses to fosfomycin using TraDIS-Xpress reveals novel roles for phosphonate degradation and phosphate transport systems. J Antimicrob Chemother 2020; 75:3144–3151
     [Google Scholar]
  28. Elwell LP, Ferone R, Freeman GA, Fyfe JA, Hill JA et al. Antibacterial activity and mechanism of action of 3’-azido-3’-deoxythymidine (BW A509U. Antimicrob Agents Chemother 1987; 31:274–280 [View Article]
     [Google Scholar]
  29. Wambaugh MA, Shakya VPS, Lewis AJ, Mulvey MA, Brown JCS et al. High-throughput identification and rational design of synergistic small-molecule pairs for combating and bypassing antibiotic resistance. PLoS Biol 2017; 15:e2001644 [View Article] [PubMed]
     [Google Scholar]
  30. Santiago M, Lee W, Fayad AA, Coe KA, Rajagopal M et al. Genome-wide mutant profiling predicts the mechanism of a Lipid II binding antibiotic. Nat Chem Biol 2018; 14:601–608 [View Article] [PubMed]
     [Google Scholar]
  31. Nichols RJ, Sen S, Choo YJ, Beltrao P, Zietek M et al. Phenotypic landscape of a bacterial cell. Cell 2011; 144:143–156 [View Article] [PubMed]
     [Google Scholar]
  32. Neu HC, Kamimura T. Synergy of fosmidomycin (FR-31564) and other antimicrobial agents. Antimicrob Agents Chemother 1982; 22:560–563
     [Google Scholar]
  33. Zhang B, Watts KM, Hodge D et al. A second target of the antimalarial and antibacterial agent fosmidomycin revealed by cellular metabolic profiling. Biochemistry 2011; 50:3570–3577
     [Google Scholar]
  34. Connor TR, Loman NJ, Thompson S, Smith A, Southgate J et al. CLIMB (the Cloud Infrastructure for Microbial Bioinformatics): an online resource for the medical microbiology community. Microb Genom 2016; 2:e000086 [View Article] [PubMed]
     [Google Scholar]
  35. Keseler IM, Mackie A, Santos-Zavaleta A, Billington R, Bonavides-Martínez C et al. The EcoCyc database: reflecting new knowledge about Escherichia coli K-12. Nucleic Acids Res 2017; 45:D543–D550 [View Article]
     [Google Scholar]
  36. Athar A, Füllgrabe A, George N, Iqbal H, Huerta L et al. ArrayExpress update – from bulk to single-cell expression data. Nucleic Acids Res 2019; 47:D711–D715 [View Article]
     [Google Scholar]
http://instance.metastore.ingenta.com/content/journal/mgen/10.1099/mgen.0.000718
Loading
Chemical biology-whole genome engineering datasets predict new antibacterial combinations
M Gen 7, 000718 (2021); https://doi.org/10.1099/mgen.0.000718
/content/journal/mgen/10.1099/mgen.0.000718
/content/journal/mgen/10.1099/mgen.0.000718
Loading

Data & Media loading...

Supplements

Supplementary material 1

EXCEL

Most cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error